Pitch,c-geru.com,.325-Inch,Chain,20BPX100U,/Cuna518575.html,.050-Inc,Saw,Micro-Chisel,Patio, Lawn Garden , Outdoor Power Tools , Replacement Parts Accessories,$241,Oregon Oregon 20BPX100U Micro-Chisel Quantity limited Saw Pitch Chain .050-Inc .325-Inch Pitch,c-geru.com,.325-Inch,Chain,20BPX100U,/Cuna518575.html,.050-Inc,Saw,Micro-Chisel,Patio, Lawn Garden , Outdoor Power Tools , Replacement Parts Accessories,$241,Oregon Oregon 20BPX100U Micro-Chisel Quantity limited Saw Pitch Chain .050-Inc .325-Inch $241 Oregon 20BPX100U Micro-Chisel Saw Chain .325-Inch Pitch .050-Inc Patio, Lawn Garden Outdoor Power Tools Replacement Parts Accessories $241 Oregon 20BPX100U Micro-Chisel Saw Chain .325-Inch Pitch .050-Inc Patio, Lawn Garden Outdoor Power Tools Replacement Parts Accessories

Oregon 20BPX100U Micro-Chisel Quantity limited Saw Limited time sale Pitch Chain .050-Inc .325-Inch

Oregon 20BPX100U Micro-Chisel Saw Chain .325-Inch Pitch .050-Inc

$241

Oregon 20BPX100U Micro-Chisel Saw Chain .325-Inch Pitch .050-Inc

|||

Product description

The 20BPX100U ControlCut Saw Chain reel contains 100 feet of 20BPX chain, an ideal choice for occasional chainsaw users such as property owners and commercial cutters. This .325" pitch, .050" gauge chain features a low kickback design and low-vibration, Micro Chisel cutters with small radius working corners for excellent performance and easy maintenance. Compatible fit with Husqvarna H22X 100U and 503306701 as well as Stihl 23RM3 100R. Replaces many OEM parts, including but not limited to the following: Stihl - 23RM3 100R, Husqvarna - H22X 100U, Husqvarna - 503306701


From the manufacturer

Oregon 20BPX100U Micro-Chisel Saw Chain .325-Inch Pitch .050-Inc

CURRENT ISSUE
November, 2021

No. 106 (11)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma

Transducin β-like protein 1 (TBL1) plays a crucial role in controlling the stability of regulatory proteins involved in cell proliferation and autophagy induction. This study revealed that, unlike normal B cells, diffuse large B-cell lymphoma cells express abundant levels of TBL1 and its overexpression correlates with poor clinical outcome. Targeting TBL1 promoted lymphoma cell death in vitro and in vivo. These results provide the rationale for targeting TBL1 as a novel therapeutic strategy in diffuse large B-cell lymphoma.

Youssef Youssef et al.

Article

Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro

The authors of this study developed a single-chain antibody that targets a shear gradient-specific conformation of von Willebrnad factor (VWF). In vitro studies showed that this antibody specifically reduces VWF-GPIbα binding and thrombus formation at sites of shear rate gradients but does not block platelet deposition and aggregation under constant shear rate. This characteristic places the antibody in a new class of antiplatelet therapy for selective blockade of pathological thrombus formation while maintaining normal hemostasis.

Thomas Hoefer et al.

Case Report

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia

A 26-year-old female developed vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis and bi-hemispheric hemorrhage following the first dose of the ChAdOx1 nCoV-19 vaccine. The treatment protocol, based on intravenous immunoglobulins, dexamethasone and argatroban was successful with almost complete clinical, laboratory and radiological response. This experience supports the application of an early and multidisciplinary therapeutic approach in cases of VITT, with the possibility of avoiding deaths and obtain a resolution of the syndrome.

Sara Bonato et al.

Letter

Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience

This retrospective study compared the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in 23 patients with hematologic malignancies transplanted from non-sibling fully matched related donors to that of patients who underwent conventional haplo-HSCT. Subjects transplanted from fully matched related donors showed trends to a higher relapse rate and lower cumulative incidence of grade II-IV acute graft-versus-host disease, but overall survival was similar. The authors concluded that individualized adjustment of the immunosuppressive treatment is reasonable for this category of patients.

Yaoyao Shen et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA